Assessing the Efficacy of Treatment with Vitamin C and Hydrocortisone in Children Admitted to Intensive Care Unit with Septic Shock.
Resuscitation in Paediatric Sepsis using Vitamin C and Hydrocortisone - A Randomized Controlled Multicentre Trial - assessing the effect on time alive and free of vasopressors
The University of Queensland
384 participants
Dec 19, 2021
Interventional
Conditions
Summary
Globally, a child dies from sepsis every 30 seconds. In Australia, one child dies every week, and many surviving children experience long term disability. We hypothesise that treatment of septic children with vitamin C and hydrocortisone will result in earlier shock resolution. We will perform a worldwide randomised controlled trial in paediatric sepsis which will test the use of Vitamin C (100 mg/kg 6 h) and Hydrocortisone (1 mg/kg 6 h) which has shown some promise in improving patient-centred outcomes in adults. The study will assess functional outcomes and quality of life, consumer engagement, and sepsis related costs. The wide dissemination of findings will increase awareness of sepsis and could save lives. In addition, we aim to establish a biobank of patient samples enrolled in the trial for sepsis biomarker studies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will be allocated in a 1:1:1 ratio to the RESPOND treatment groups. Arm 1 - Intervention 1 - Early intravenous resuscitation with Vitamin C and Hydrocortisone. After initial shock treatment including fluids and a first intravenous inotrope, patients then receive concomitant treatment with Vitamin C and Hydrocortisone. Ascorbic acid (Vitamin C): the dosing schedule is 100 mg/kg (maximum 5,000 mg per dose) intravenously every 6 hours for the duration of study treatment and will be infused over 60 minutes. Hydrocortisone: The dosing schedule is 1 mg/kg (maximum 50 mg per dose) intravenously infused over 5 minutes every 6 hours for the duration of study treatment given as a slow bolus. Arm 2 - Intervention 2 - Hydrocortisone only. Hydrocortisone: the dosing schedule is 1mg/kg (maximum 50 mg per dose) intravenously infused over 5 minutes every 6 hours for the duration of study treatment given as a slow bolus. All three arms will be monitored for adherence to interventions by a formal data monitoring and audit of the medication records. Duration of treatment After shock resolution - defined as cessation of inotropes for at least 4 hours - or after a maximum of 72hours study drugs should be ceased. The treatment will continue until (whichever occurs first): - Septic shock resolves defined as ability to cease inotropes for less than 4 hours with good perfusion and no signs of shock. - 72 hours of treatment has been administered - The patient is discharged from ICU - Contraindications to Vitamin C or Hydrocortisone therapy arise - Death occurs - Serious adverse events suspected to be secondary to the intervention therapy develop
Locations(15)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621000247875